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Metastasis, the spread and growth of tumours at secondary sites, is an extremely important clinical event, since a majority of cancer
mortality is associated with the metastatic tumours, rather than the primary tumour. In spite of the importance of metastasis in the
clinical setting, the actual process is extremely inefficient. Millions of tumour cells can be shed into the vasculature daily; yet, few
secondary tumours are formed. The classical hypothesis explaining the inefficiency was a series of secondary events occurring in the
tumour, resulting in a small subpopulation of cells capable of completing all of the steps required to successfully colonise a distant site.
However, recent discoveries demonstrating the ability to predict metastatic propensity from gene expression profiles in bulk tumour
tissue are not consistent with only a small subpopulation of cells in the primary tumour acquiring metastatic ability, suggesting that
metastatic ability might be pre-programmed in tumours by the initiating oncogenic mutations. Data supporting both of these
seemingly incompatible theories exist. Therefore, to reconcile the observed results, additional variables need to be added to the
model of metastatic inefficiency. One possible variable that might explain the discrepancies is genetic background effects. Studies have
demonstrated that the genetic background on which a tumour arises on can have significant affects on the ability of the tumour to
metastasise and on gene expression profiles. Thus, the observations could be reconciled by combining the theories, with genetic
background influencing both metastatic efficiency and predictive gene expression profiles, upon which, subsequently, metastasis-
promoting mutational and epigenetic events occur. If the genetic background is an important determinant of metastatic efficiency, it
would have significant implications for the clinical prediction and treatment of metastatic disease, as well as for the design of potential
prevention strategies.
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Metastasis is an extraordinarily complex process. To successfully
colonise a secondary site, a cancer cell must complete a sequential
series of steps before it becomes a clinically detectable lesion.
These steps include separation from the primary tumour, invasion
through surrounding tissues and basement membranes, entry and
survival in the circulation, lymphatics or peritoneal space,
arresting in a distant target organ, usually, but not always
(Al-Mehdi et al, 2000) followed by extravasation into the
surrounding tissue, survival in the foreign microenvironment,
proliferation, and induction of angiogenesis, all the while evading
apoptotic death or immunological response (reviewed in Liotta
and Stetler-Stevenson, 1993).
This process is of great importance to the clinical management
of cancer, since the majority of cancer mortality is associated with
metastatic disease rather than the primary tumour (Liotta and
Stetler-Stevenson, 1993). In most cases, cancer patients with
localised tumours have significantly better prognoses than those
with disseminated tumours. Since recent evidence suggests that the
first stages of metastasis can be an early event (Schmidt-Kittler
et al, 2003) and that 60–70% of patients have initiated the
metastatic process by the time of diagnosis, better understanding
of the factors leading to tumour dissemination is of vital
importance. However, even patients who have no evidence of
tumour dissemination at primary diagnosis are at risk for
metastatic disease. Approximately one-third of women who are
sentinel lymph node negative at the time of surgical resection of
the primary breast tumour will subsequently develop clinically
detectable secondary tumours (Heimann et al, 2000). Even patients
with small primary tumours and node-negative status (T1N0) at
surgery have a significant (15–25%) chance of developing distant
metastases (Heimann and Hellman, 2000).
In spite of the prevalence of secondary tumours in cancer
patients, the metastatic process is an extremely inefficient process.
To successfully colonise a distant site, a cancer cell must complete
all of the steps of the cascade. Failure to complete any step results
in the failure to colonise and proliferate. As a result, tumours can
shed millions of cells into the bloodstream daily (Butler and
Gullino, 1975); yet, very few clinically relevant metastases are
formed (Tarin et al, 1984). Although many steps in the metastatic
process are thought to contribute to metastatic inefficiency, our
incomplete understanding of this process suggests that we are
aware of some but not all of these key regulatory points. For
instance, killing of intravasated cells by haemodynamic forces and
sheering has been thought be a major source of metastatic
inefficiency (Weiss et al, 1992). However, recent evidence suggests
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vasculature may not always be a major source of metastatic
inefficiency. Cells in the bloodstream have been shown to arrest in
capillary beds and extravasate with high efficiency and reside
dormant in the secondary sites for long periods of time (Luzzi et al,
1998), sometimes for years (Riethmuller and Klein, 2001).
Micrometastases may form, but the bulk of these preclinical
lesions appear to regress (Luzzi et al, 1998), probably due to
apoptosis (Wong et al, 2001).
GENETIC MODULATION OF METASTASIS
The first suggestion of the role of genetic background as a critical
determinant of metastatic potential was derived from transfection
experiments. Introduction of proto-oncogenes can induce tumor-
igenicity and metastatic potential when transfected into NIH-3T3
cells. However, when the same oncogenes were transfected into cell
lines derived from different strains of mice, metastatic potential,
but not tumorigenicity, was lost (Muschel et al, 1985; Tuck et al,
1990). These results suggested either that secondary mutations in
metastasis-promoting or -suppressing genes were differentially
present among the cell lines, or that allelic differences derived from
the inbred strain progenitor were capable of modulating metastatic
potential.
More compelling evidence for the existence of allelic variation
influencing metastatic efficiency comes from experiments from
our laboratory. These studies are based on the use of highly
metastatic mouse mammary model, the FVB/N-TgN(MMTV-
PyVT)
634Mul mouse (Guy et al, 1992). This animal carries the
mouse polyoma virus middle T antigen expressed from the mouse
mammary tumour virus enhancer and promoter. Expression of the
transgene induces synchronous multi-focal mammary tumours in
all of the mammary glands of virgin female animals, and greater
than 85% of these animals develop pulmonary metastases by 100
days of age (Guy et al, 1992).
To determine whether there was genetic modulation of
metastatic progression, the genetic background that the tumour
arose on was varied by a simple breeding strategy. The PyVT
mouse was bred to a variety of different inbred strains selected
from different branches of the mouse phylogenic tree (Beck et al,
2000) to survey a broad range of the allelic diversity captured in
the inbred strains. The F1 progeny were aged to permit tumour
induction and potential metastatic dissemination. Subsequently,
the lungs were examined to determine whether introduction of
allelic variation had an affect on the density of pulmonary
metastases, and a wide variation in metastatic efficiency was
observed (Lifsted et al, 1998). Since all of the tumours were
induced by the same genetic event, expression of PyVT, the most
likely explanation for this variation is that subtle genetic
differences between the strains are affecting the metastasis process.
Further evidence of the effect of background on metastatic
efficiency was obtained by genetic mapping experiments. Using
quantitative trait mapping strategies, three backcross mapping
experiments and a recombinant inbred cross were analysed to
identify chromosomal regions associated with metastatic effi-
ciency. Two statistically significant associations were observed,
one on chromosome 6 and the other on 19 (Hunter et al, 2001). In
addition, suggestive associations were reproducibly observed for
several other chromosomal regions. The ability to map metastasis
efficiency loci within an inbred strain genome argues against
random somatic mutations being the major determinant of
metastatic efficiency, since each individual animals would retain
different sets of alterations, precluding meiotic mapping.
Understanding the events and factors that influence tumour
dissemination is clearly of great importance for the development of
more effective prevention or clinical interventions. Recent studies
have sparked considerable debate in the literature on the subject.
Several studies were published that demonstrated the ability to
classify primary tumours as metastatic or nonmetastatic, based on
gene expression from bulk tumour tissue (van ’t Veer et al, 2002;
Ramaswamy et al, 2003). Since a substantial portion of the tumour
must exhibit a particular expression pattern to be detectable in
microarray experiments, the authors interpret their data to suggest
that metastatic capacity is likely to be encoded early in
tumorigenesis by the particular collections of oncogenic events
that initiate the tumour. As supporting evidence, the authors cite
the clinical phenomenon of patients with metastatic disease, but
unknown primary cancer (UPC). These patients, estimated at
approximately 5% of cases, present with disseminated disease, but
have no clinically detectable primary tumour or only a small well-
differentiated lesion found at autopsy (Riethmuller and Klein,
2001). The lack of large primary tumour mass could suggest that
there were insufficient numbers of cells to achieve the necessary
sequence of events predicted by the stochastically driven progres-
sion model.
In contrast, the generally accepted progression model predicts
that only a small subpopulation of the tumour would attain
metastatic capacity and therefore would not be less likely to
dominate the average gene expression profile of bulk tumour
tissue. However, compelling evidence for the progression model
exists. For example, consistent reproducible chromosomal aberra-
tions are often specifically associated with disseminated tumours
rather than the primary tumours. The rapidly growing collection of
metastasis suppressors, those genes whose reintroduction into
tumour cells specifically interferes with metastatic colonisation
without affecting primary tumour initiation or growth kinetics,
impact virtually every known step in the metastatic process
(Kauffman et al, 2003; Shevde and Welch, 2003; Steeg, 2003). The
statistical likelihood of stochastic events predicted by the model
resulting in the appropriate combination of metastasis-associated
genomic alterations is small, consistent with the poor efficiency of
the process. Although recent evidence suggests that some of these
aberrations may occur subsequent to dissemination (Schmidt-
Kittler et al, 2003), the fact that metastases are often clonal in
nature (Fidler and Kripke, 1977) supports the hypothesis that there
is a specific subpopulation within the heterogenous primary
tumour that these cells originate from.
The truth is likely to be a blend of the models, with additional
variables added in. One of these variables is likely the affect of
genetic background as a determinant of metastasis. As previously
mentioned, we demonstrated that the genetic background on
which a cancer arises has a significant affect on the ability of
mammary tumours to successfully colonise the lung. In addition,
we and others (Eaves et al, 2002; Qiu et al, 2003) have
demonstrated that genetic background significantly influences
gene expression, including the metastasis signature genes.
The expression of the 17-gene metastasis signature set described
by Ramaswamy et al (2003) was examined between the high
metastatic FVB/NJ background with the low metastatic (NZB/
B1NJFVB/NJ)F1 background. Of the 17 mouse orthologs, 16
were expressed in the PyVT tumour model used in our laboratory.
Out of 16, 15 showed the same direction of expression as observed
in the human primary vs metastasis (Hunter et al, 2003; Qiu et al,
2003; Ramaswamy et al, 2003). Similar results are observed
comparing FVB/NJ tumours with another low metastatic genotype
((DBA/2JFVB/NJ)F1; K Hunter, unpublished results). These
observations suggest that the propensity of a tumour to
metastasise, and the predictive gene expression profile, is at least
in part set by the combination of subtle changes in gene function,
mediated by polymorphisms in coding sequence, splice sites,
promoters, and enhancers, before tumour initiation. Subsequently
progressive events such as translocations, deletions, etc., occur to
produce rare cells that are capable of completing the metastatic
process. The allelic background of the tumour would also likely
influence what specific secondary events would be necessary in
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metastatic cascade.
Importantly, the genetic efficiency determinant not only exerts
its affects within the tumour cell itself, but also in the primary
tumour stroma as well as the microenvironment at distant sites.
Target organ microenvironment is known to play an important
role in metastasis formation (Fidler, 2002). Tumour cells are
known to require normal stroma for important signalling events
(Alessandro and Kohn, 2002). Expression of important metastasis-
related genes has been shown to be expressed not only in the
tumour cells but also in the target tissue (Muller et al, 2001). As a
result, polymorphisms that alter the function of normal tissue
functions, for example, promoter polymorphisms altering cytokine
levels, missense polymorphisms affecting adhesion molecule
function, alterations in signaling cascades, etc., may be as
important a barrier to successful metastatic colonisation as
alterations occurring within the tumour cell itself. Alternatively,
relevant polymorphisms might indirectly affect important genes by
altering epigenetic controls. Several metastasis suppressors have
been shown to be epigenetically downregulated during dissemina-
tion (e.g. Domann et al, 2000), rather than inactivated by mutation
or deletion. Since it has been shown that endogenous genes can be
differentially imprinted in mouse strains (Jiang et al, 1998),
polymorphisms that affect more global gene expression by
modulating DNA methylation of histone modification must also
be considered as potential metastasis modulating functions.
The growing evidence suggesting that the majority of tumour
cells are capable of extravasating (Naumov et al, 2002) suggest that
proliferation in the secondary sites may in fact be one of the most
important determinants to whether cells proliferate into a
secondary tumour or undergo apoptosis. Since the growth of
disseminated cells to clinically relevant macroscopic lesions is
dependent upon angiogenesis, the effect of genetics on this process
might be another important source of metastatic efficiency
modulation. Inbred strains of mice are known to be different in
their angiogenic response to at least some growth factors (Rohan
et al, 2000). Differences in the ability of the target stroma in
different genotypes to support angiogenic conversion from
microscopic to macroscopic secondary lesions in response to
tumour-secreted growth factors might therefore play an important
role in the efficiency of the development of clinically relevant
secondary tumours. Furthermore, it is conceivable that allelic
variation may affect escape from immune surveillance. Subtle
variations in the ability of the host to mount an effective cytolytic
defense, coupled with the ability of highly malignant cells to
downregulate tumour-specific antigens (Schirrmacher et al, 1982),
might also play an important role in metastatic efficiency. It is
unclear at present which of these, or other cellular or molecular
processes or combinations of all, might be responsible for genetic
modulation of metastasis. Clearly, this complex and complicated
process will require a great deal of additional research to explore
and characterise the critical interplay between inherited, somatic,
and epigenetic interactions that influence metastatic progression.
IMPLICATIONS
These observations, particularly the microarray data, have
important implications for metastasis detection and management.
If genetic background is a major influence on metastatic potential,
as measured by predictive gene expression patterns in normal and
tumour tissue, it suggests that, like cancer susceptibility, there may
be individuals or families present in the human population that are
more susceptible to disseminated disease. It may therefore be
possible to identify these individuals before they develop
neoplastic disease, so that they might be more aggressively treated
with neo-adjuvant therapies immediately upon diagnosis of the
primary tumour. Alternatively, since tumour dissemination often
appears to be an early event, it is theoretically possible that a
chemoprevention regime might be developed that would prevent
tumour metastasis before the primary tumour was clinically
apparent, enabling the bulk of human cancer to be cured by
surgical resection.
In conclusion, the identity of the genomic elements in the host
background modifying metastatic efficiency is currently unknown.
They clearly warrant further investigations, since the majority of
the genetically defined regions are not associated with known
metastasis-suppressor genes. The metastasis suppressors that are
associated with our genetically defined regions do not have any
apparent molecular defects nor expression level differences
between the high and low metastatic genotypes (Park et al, 2002;
Qiu et al, 2003). Identification and characterisation of these
metastasis efficiency-modifier genes may therefore yield novel
targets to develop chemoprevention agents or antimetastatic
therapies. Preliminary evidence of the feasibility of such a strategy
is currently ongoing in our laboratory. Using a small-molecule
agent, we have demonstrated a significant reduction in the
efficiency of pulmonary colonisation, as well as modulation of
the expression profile of an independent set of metastasis-
associated genes (Yang, Lukes, Rouse, Lancaster, and Hunter,
manuscript in preparation). The new strategies could be developed
to either kill occult metastases or possibly increase the inefficiency
of the myriad tasks necessary to generate a clinically relevant
metastasis to the point where the odds of solitary, dispersed cancer
cells successfully completing the metastatic cascade to become
clinically relevant lesions approach zero.
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